FOLH1 and prostate carcinoma: The proposed methodology for protocol simplification can be applied universally, both to evaluate different patient cohorts in prostate cancer, as well as the use of different PSMA tracers (for example PSMA-11, PSMA-1007 and PSMA-I&T instead of PSMA-617), and even for different radionuclide therapies.